Omeros reports primate data for OncotoX-AML program
Omeros reported initial nonhuman primate data for OncotoX-AML in acute myeloid leukemia. One treatment course reduced myeloid progenitor cells by up to 99% and was well tolerated.
Azacitidine
DrugAlso known as: AZA
Drug Profile
Azacitidine is an antineoplastic nucleoside analogue medicine used in myelodysplastic syndrome and myeloid leukemias. It is marketed under brands including Vidaza and Onureg. Its activity includes hypomethylating and cytotoxic effects depending on dosing context.
- Drug Class
- Antineoplastic nucleoside analogue; hypomethylating agent
- Approval Status
- FDA approved for myelodysplastic syndrome on May 19, 2004; prescription-only
- Mechanism of Action
- At low doses inhibits DNA methyltransferase causing DNA hypomethylation; at higher doses causes direct cytotoxicity via DNA/RNA incorporation
- Vidaza
- Azadine
- Onureg
- \Myelodysplastic syndrome\
- \Myeloid leukemia\
- \Juvenile myelomonocytic leukemia\
Related News
Neuromyelitis Optica Spectrum Disorder Pipeline Shows 10+ Active Therapies in Development
Over 10 companies are developing 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder, including Roche's satralizumab Phase III pediatric trial and multiple anti-CD20 monoclonal antibody candidates.
Faron's Bexmarilimab Data Accepted for BSH Presentation; New AML Study Launched
Faron Pharmaceuticals announces acceptance of bexmarilimab Phase I/II data for poster presentation at BSH 2026, while launching a new Phase II BEAM-X study evaluating the drug in AML patients post-stem cell transplantation.
Faron Initiates Phase II BEAM-X Trial for Post-Transplant AML Relapse Prevention
Faron Pharmaceuticals announces Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in MRD-positive AML patients after stem cell transplantation. The Nordic AML Group-led trial will enroll 24 patients with first results expected 12-15 months after enrollment begins in Q3 2026.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07581002 |
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07548983 |
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation |
NOT_YET_RECRUITING | PHASE1 |
| NCT07539818 |
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML |
NOT_YET_RECRUITING | PHASE3 |
| NCT07508982 |
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07490288 |
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML |
NOT_YET_RECRUITING | NA |
| NCT07486726 |
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07486479 |
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML |
NOT_YET_RECRUITING | PHASE3 |
| NCT07478991 |
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07469046 |
VAH vs VA in Newly Diagnosed Elderly AML |
NOT_YET_RECRUITING | PHASE3 |
| NCT07458542 |
Effectiveness and Safety of ONUREG (Oral Azacitidine) in Chinese Patients With Acute Myeloid Leukemia |
ACTIVE_NOT_RECRUITING |